Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 0.92 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.92 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.92 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.92 |
| ▸ | PGR | P06401 | 3/20 | 0.92 |
| ▸ | TSHR | P16473 | 2/20 | 0.92 |
| ▸ | AR | P10275 | 2/20 | 0.92 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.92 |
| ▸ | MEN1 | O00255 | 1/20 | 0.92 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.92 |
| ▸ | APEX1 | P27695 | 1/20 | 0.92 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.92 |
| ▸ | IKBKB | O14920 | 1/20 | 0.92 |
| ▸ | CHUK | O15111 | 1/20 | 0.92 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.92 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.92 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.92 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexamethasone SCHEMBL1301204 | 1.00 | HIF1A (0.92) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL2807697 | 1.00 | HIF1A (0.92) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL1479323 | 1.00 | HIF1A (0.92) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL29199226 | 0.99 | HIF1A (0.90) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL29199225 | 0.99 | HIF1A (0.90) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL5501682 | 0.99 | HIF1A (0.93) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL8529637 | 0.99 | HIF1A (0.93) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL73250 | 0.99 | HIF1A (0.93) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL1561578 | 0.99 | HIF1A (0.93) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL7426 | 0.99 | HIF1A (0.93) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190167601-A1 | APPARATUS AND METHOD FOR ZERO ORDER DRUG DELIVERY FROM MULTILAYER AMPHIPHILIC CO-NETWORKS | THE UNIVERSITY OF AKRON (US) | 2019-06-06 | — | — | US | claimed |
| WO-2018004797-A1 | APPARATUS AND METHOD FOR ZERO ORDER DRUG DELIVERY FROM MULTILAYER AMPHIPHILIC CO-NETWORKS | THE UNIVERSITY OF AKRON (US) | 2018-01-04 | — | — | WO | claimed |
| CN-118302171-A | Lymphocyte populations and methods for producing the same | AVM生物技术有限责任公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118215450-A | System and method for coating bone material | 华沙整形外科股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-118202231-A | System and method for identifying a coating on an implant | 华沙整形外科股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-117899058-A | Film for treating dental ulcer and preparation method thereof | 桂林南药股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-115634081-A | Bone material dispensing system and method of use | 华沙整形外科股份有限公司 | 2023-01-24 | — | — | CN | disclosed |
| CN-115364122-A | Compositions comprising bacterial strains | 4D制药研究有限公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-115243685-A | Pharmaceutical compositions for treating or preventing various inflammatory disorders | 阿达瓦克治疗公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-114984057-A | Compositions comprising bacterial strains | 4D制药研究有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114955210-A | Container for storing, mixing and transporting bone material | 华沙整形外科股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20100330146-A1 | CONTACT LENSES FOR EXTENDED RELEASE OF BIOACTIVE AGENTS CONTAINING DIFFUSION ATTENUATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100240916-A1 | PROCESS FOR OBTAINING STEROIDAL PHOSPHATE COMPOUNDS | HOVIONE INTER LIMITED (CH) | 2010-09-23 | — | — | US | disclosed |
| CN-101742987-A | Be used to obtain the method for steroidal phosphate compounds | HOVIONE INT LTD | 2010-06-16 | — | — | CN | disclosed |
| EP-2148657-A2 | PROCESS FOR OBTAINING STEROIDAL PHOSPHATE COMPOUNDS | Hovione Inter Ltd. (CH) | 2010-02-03 | — | — | EP | disclosed |
| WO-2009094466-A2 | CONTACT LENSES FOR EXTENDED RELEASE OF BIOACTIVE AGENTS CONTAINING DIFFUSION ATTENUATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2008139210-A2 | PROCESS FOR OBTAINING STEROIDAL PHOSPHATE COMPOUNDS | HOVIONE INTER LTD. (CH) | 2008-11-20 | — | — | WO | disclosed |
| CN-101125128-A | Sustained-release tablet composition of pramipexole | PHARMACIA CORP (US) | 2008-02-20 | — | — | CN | disclosed |
| CN-1323663-C | Sustained release tablet containing reboxetine | PHARMACIA CORP (US) | 2007-07-04 | — | — | CN | disclosed |
| CN-1671383-A | Sustained release tablet containing reboxetine | PHARMACIA CORP (US) | 2005-09-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167601-A1 | APPARATUS AND METHOD FOR ZERO ORDER DRUG DELIVERY FROM MULTILAYER AMPHIPHILIC CO-NETWORKS | EFNA1, ABCE1, EPHA2 | NR3C1 2859/4885HIF1A 2100/4885CYP3A4 884/4885 |
| US-20100240916-A1 | PROCESS FOR OBTAINING STEROIDAL PHOSPHATE COMPOUNDS | HSD3B1, CYP17A1, HSD3B2 | NR3C1 38/4885HIF1A 2456/4885CYP3A4 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.